Long-Term Safety and Efficacy of Mirogabalin for Central Neuropathic Pain: A Multinational, Phase 3, 52-Week, Open-Label Study in Asia

Long-Term Safety and Efficacy of Mirogabalin for Central Neuropathic Pain: A Multinational, Phase 3, 52-Week, Open-Label Study in Asia

Abstract Introduction Central neuropathic pain (CNeP) is difficult to treat and has diverse etiology, including spinal cord injury (CNePSCI), Parkinson’s disease (CNePPD), and central post-stroke pain (CPSP). The safety and efficacy of mirogabalin have been demonstrated in short-term trials, includi...

Full description

Bibliographic Details
Main Authors: Takahiro Ushida, Yoichi Katayama, Yoichi Hiasa, Makoto Nishihara, Fumihiro Tajima, Shinsuke Katoh, Hirotaka Tanaka, Takeshi Maeda, Kazunari Furusawa, Yoshihiro Kakehi, Kunika Kikumori, Masanori Kuroha
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-04-01
Series:Pain and Therapy
Subjects:
Central neuropathic pain
Efficacy
Gabapentinoid
Mirogabalin
Open-label
Parkinson’s disease
Online Access:https://doi.org/10.1007/s40122-023-00513-1

Internet

https://doi.org/10.1007/s40122-023-00513-1

Similar Items